Physician profile
Greg N Smith
NPI 1649257866
$16,437.29
in general payments reported to CMS, 2019-2025
75 companies · $3,954 in 2025
The $3,954 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,152 · 2020: $524 · 2021: $113 · 2022: $1,150 · 2023: $3,556 · 2024: $4,988 · 2025: $3,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,233.63 |
| Education | $264.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,652.62 | 2020-2025 | Qulipta, Ubrelvy, Botox |
| Ucb, INC. | $1,645.86 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Alexion Pharmaceuticals, INC. | $1,044.75 | 2019-2025 | Ultomiris, Soliris |
| Noctrix Health, INC. | $790.23 | 2025 | Nidra |
| Csl Behring | $672.07 | 2019-2025 | Hizentra |
| Eisai INC. | $643.14 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $638.53 | 2019-2025 | Nuplazid |
| Argenx US, INC. | $561.52 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Lilly USA, LLC | $542.44 | 2022-2025 | Amyvid, Kisunla, Emgality |
| Novartis Pharmaceuticals Corporation | $527.44 | 2019-2025 | |
| Pfizer INC. | $514.54 | 2019-2025 | |
| Tg Therapeutics, INC. | $445.19 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $425.12 | 2022 | |
| Amneal Pharmaceuticals LLC | $403.51 | 2022-2025 | Ongentys, Rytary, Crexont |
| Catalyst Pharmaceuticals, INC. | $377.07 | 2023-2025 | Fycompa |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $350.09 | 2019-2025 | Uplizna, Aimovig |
| Banner Life Sciences, LLC | $320.78 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $320.02 | 2024-2025 | Hyqvia |
| Genzyme Corporation | $267.60 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $252.37 | 2019-2025 | Onpattro, Givlaari |
| Neurelis, INC. | $224.57 | 2022-2025 | Valtoco |
| Genentech USA, INC. | $223.19 | 2023-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Braeburn INC. | $193.20 | 2023-2024 | Brixadi |
| Optos, INC. | $191.24 | 2019 | |
| Grifols USA, LLC | $185.24 | 2019-2025 | Gamunex-C |
| Monteris Medical Corporation | $183.73 | 2025 | Neuroblate |
| Emd Serono, INC. | $167.48 | 2024-2025 | |
| Biogen, INC. | $166.87 | 2023-2025 | Vumerity, Tysabri |
| Mdd US Operations, LLC | $160.32 | 2019-2023 | Gocovri |
| Octapharma USA, INC. | $156.12 | 2023-2025 | Panzyga |
| Teva Pharmaceuticals USA, INC. | $149.50 | 2019-2025 | Austedo Xr, Austedo Xr |
| Allergan, INC. | $148.81 | 2019 | |
| Vanda Pharmaceuticals INC. | $147.36 | 2024-2025 | Ponvory, Fanapt |
| Novo Nordisk INC | $119.70 | 2024 | |
| Sk Life Science, INC. | $110.16 | 2022-2025 | |
| Janssen Biotech, INC. | $100.99 | 2025 | |
| Chiesi USA, INC. | $97.35 | 2019-2025 | Cleviprex |
| Acorda Therapeutics, INC | $96.03 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $93.03 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $78.08 | 2023-2025 | Horizant, Horizant |
| Akcea Therapeutics, INC. | $77.32 | 2019 | |
| Janssen Pharmaceuticals, INC | $67.40 | 2019-2025 | Xarelto |
| Celgene Corporation | $59.76 | 2025 | Zeposia |
| Astrazeneca Pharmaceuticals LP | $49.70 | 2023-2024 | Andexxa |
| Boston Scientific Corporation | $49.30 | 2019-2020 | |
| Promius Pharma LLC | $46.05 | 2019 | |
| Livanova USA, INC. | $42.38 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Tanabe Pharma America, INC. | $41.64 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $41.61 | 2019-2020 | |
| Aprecia Pharmaceuticals, LLC | $40.70 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $37.46 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $33.68 | 2024 | Ingrezza |
| Kyowa Kirin, INC. | $33.61 | 2023-2024 | Nourianz |
| Otsuka America Pharmaceutical, INC. | $32.10 | 2023-2024 | Rexulti, Nuedexta |
| Vertical Pharmaceuticals, LLC | $30.16 | 2019 | |
| Abbott Laboratories | $30.04 | 2023-2025 | Infinity |
| Springworks Therapeutics, INC. | $29.05 | 2025 | Gomekli |
| Axsome Therapeutics, INC. | $25.43 | 2025 | Symbravo |
| Genentech, INC. | $23.98 | 2024 | Ocrevus |
| Vertex Pharmaceuticals Incorporated | $21.88 | 2025 | |
| Portola Pharmaceuticals, LLC | $21.12 | 2020 | |
| Lundbeck LLC | $19.81 | 2024 | Abilify Asimtufii |
| Averitas Pharma INC. | $19.34 | 2025 | Qutenza |
| Gilead Sciences, INC. | $19.34 | 2025 | |
| Impel Pharmaceuticals INC. | $18.10 | 2023 | Trudhesa |
| Merz Pharmaceuticals, LLC | $17.89 | 2024 | Xeomin |
| Sumitomo Pharma America, INC. | $17.49 | 2024 | Aptiom |
| Assertio Therapeutics, INC. | $16.06 | 2019 | |
| Upsher-Smith Laboratories LLC | $15.99 | 2022 | |
| Travere Therapeutics, INC. | $13.92 | 2019 | |
| Zyla Life Sciences, INC. | $13.73 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.53 | 2022 | |
| Currax Pharmaceuticals LLC | $11.74 | 2020 | |
| Tris Pharma INC | $11.60 | 2019 | |
| Aucta Pharmaceuticals, INC. | $6.52 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.